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Background: The purpose of this study was to evaluate patient-learning and nurse-teaching 
experiences when using a redesigned prefilled, ready-to-use follitropin alfa pen injector.
Methods: Seventy-three UK women of reproductive age either administering daily treatment 
with self-injectable gonadotropins or about to start gonadotropin treatment for infertility (aged 
24–47 years; 53 self-injection-experienced and 20 self-injection-naïve) and 28 nurses from UK 
infertility clinics were recruited for the study. Following instruction, patients and nurses used 
the redesigned follitropin alfa pen to inject water into an orange and completed questionnaires 
to evaluate their experiences with the pen immediately after the simulated injections.
Results: Most (88%, n = 64) patients found it easy to learn how to use the pen. Among injection-
experienced patients, 66% (n = 35) agreed that the redesigned pen was easier to learn to use 
compared with their current method and 70% (n = 37) also said they would prefer its use over 
current devices for all injectable fertility medications. All nurses considered the redesigned 
pen easy to learn and believed it would be easy to teach patients how to use. Eighty-six percent 
(n = 24) of the nurses thought it was easy to teach patients to determine the remaining dose to 
be dialed and injected in a second pen if the initial dose was incomplete. Compared with other 
injection devices, 96% (n = 27) thought it was “much easier” to “as easy” to teach patients to 
use the redesigned pen. Based on ease of teaching, 68% (n = 19) of nurses would choose to teach 
the pen in preference to any other injection method. Almost all (93%, n = 26) nurses considered 
that having the same pen format for a range of injectable gonadotropins would facilitate teach-
ing and learning self-injection.
Conclusion: In this market research study with infertile patients and infertility nurses, the 
redesigned follitropin alfa pen was perceived as easy to learn, easy to teach how to use, and 
well accepted.
Keywords: infertility, gonadotropin, follitropin alfa pen, prefilled pen device, recombinant 
human follicle-stimulating hormone
Introduction
Daily injections of urinary or recombinant gonadotropins are often used to treat   
infertile patients and may include human follicle-stimulating hormone with or without 
the addition of luteinizing hormone. These gonadotropin products are often self-
injected to promote follicular development as part of the treatment plan for assisted 
reproductive technologies, such as ovulation induction combined with natural inter-
course, intrauterine insemination, or in vitro fertilization. At the end of the controlled 
ovarian stimulation phase with injectable gonadotropins, a single injection of human 
chorionic gonadotropin may be used to promote final follicular maturation and to 
trigger ovulation.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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The need for daily subcutaneous injections in infertility 
treatment does not tend to impair treatment adherence, but 
there is patient anxiety surrounding whether the correct dose 
has been delivered and the fact that unconscious mistakes 
can be made.1 To improve compliance with treatment, it is 
important that devices used for the administration of recom-
binant human gonadotropins are easy for patients to learn to 
use, as well as easy for nurses in charge of patient training to 
teach. Currently, the majority of gonadotropin products are 
administered via syringes or prefilled pen injection devices, 
which have been introduced in the last decade to try to 
improve patient convenience and ease of use.
A key attribute of any injection device is the number of 
steps required to prepare and administer the injection. Fewer 
and easier steps are likely to reduce injection errors and to 
contribute to patient confidence.
The original pen injector for administration of follitro-
pin alfa (recombinant human follicle-stimulating hormone) 
was modified to include built-in, enhanced, patient-friendly 
features, including visually improved numbering on the 
dose-setting dial in a second-generation pen. The third-
generation redesigned follitropin alfa pen injector used in 
this study is a multidose, ready-to-use prefilled pen that 
incorporates several new and improved features. These 
features include a dose display window with a magnifying 
glass lid to enlarge the dosing number, which shows only 
the selected preset dose, the return of the dose reading to 
zero after injection of the full prescribed dose, or informa-
tion on how much residual dose is required with a second 
pen if the full dose has not been administered, and a fully 
transparent cartridge container with graduated markings, 
to assist the user in determining the approximate amount 
of product left in the pen. The pen is available in three dose 
presentations of follitropin alfa, ie, 300 IU, 450 IU, and 900 
IU. A key feature of the pen is that it offers flexibility in 
individualization of treatment protocols with a wide range 
of dose increments, ie, 12.5–300 IU for the 300 IU pen and 
12.5–450 IU for the 450 IU and 900 IU pens. Results of 
the dose accuracy testing of the 900 IU presentation of the 
redesigned follitropin alfa pen injector, performed in accor-
dance with international standards (EN ISO 11608-1:2000), 
demonstrated that the pen can accurately deliver a wide 
range of doses.2
The objective of this market research study was to assess 
the ease of teaching by fertility nurses on how to use the 
redesigned follitropin alfa pen injector, as well as the ease 
of learning to use the pen by infertile patients undergoing 
ovarian stimulation with gonadotropins.
Materials and methods
This study was conducted in the UK in January–February 
2011 (London, Birmingham, Southampton, Manchester, 
Glasgow, and Newcastle). Patients and nurses were recruited 
by Insight Research Group, London, UK, based on the criteria 
outlined below. All participants provided informed consent.
Study participants
Patients eligible for inclusion in this study were women of 
reproductive age who were either undergoing controlled ovar-
ian stimulation or had previous experience with daily injections 
of gonadotropin products within the last 6 months, or were 
injection-naïve with no previous experience with injectable 
medications but were consulting with a fertility clinic and were 
about to start gonadotropin treatment for infertility.
Nurses working in infertility centers and responsible for 
teaching patients undergoing fertility treatment to use self-
injection devices (syringes and pens) were also included in 
the study. Nurses had to teach at least 10 patients in an average 
month, spend 80% of their working time in infertility clinics 
and have 3–30 years experience of working in an infertility 
clinic to be eligible for inclusion.
Training procedures and study 
questionnaires
Patient-learning and nurse-teaching experiences when using 
the redesigned follitropin alfa prefilled pen (GONAL-f  ®/
GONAL-f ® Revised Formulation Female Prefilled Pen, 
Merck Serono SA, Geneva, Switzerland, an affiliate of 
Merck KGaA, Darmstadt, Germany, Figure 1) were evalu-
ated in this market research study. Before a moderator pre-
sented and demonstrated the operation of the pen injector 
1
2
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Figure 1 The components of the redesigned follitropin alfa pen injector: 1, dose-
setting  knob;  2,  dose  display;  3,  plunger  piston;  4,  graduated  reservoir  holder;   
5, threaded needle connector; 6, pen cap; 7, removable needle; 8, inner needle 
shield;  9,  outer  needle  cap;  10,  peel-off  seal  tab.  The  pen  barrel  and cartridge 
comprise sections 1–5.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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to the nurses, they completed part of an online nurses’ 
questionnaire (Appendix 1) pertaining to use and percep-
tions of existing devices for administering fertility treatment. 
To ensure consistent demonstration of the pen injector, the 
moderator followed a script that outlined step-by-step writ-
ten and diagrammatic instructions. This was also available 
to nurses as additional guidance in handling the pen. After 
receiving the verbal and written instructions, nurses were 
each given a new, unbranded 900 IU demonstration pen, 
prefilled with water for injection, and were asked to attach 
the needle, practice removing large air bubbles, and inject 
125 IU of water into an orange as many times as required to 
gain familiarity with the pen injector. Nurses then completed 
the part of the nurses’ questionnaire on ease of learning. The 
nurses then repeated the process, training small groups of 
up to five patients per nurse. The moderator ensured that 
an accurate demonstration of the pen injector was provided 
to patients.
For assessment of acceptance of the redesigned fol-
litropin alfa pen, nurses completed the relevant questions 
on their questionnaire and patients completed a separate 
online patient questionnaire (Appendix 2). Each step of 
the injection process with the pen was assessed to deter-
mine both how easy it was to teach and to learn in terms 
of priming, attaching the needle, reading the dosing scale, 
setting the dose, pushing the dose setting knob when inject-
ing, and checking that the full dose had been injected. 
Respondents also evaluated how easy it was to determine 
the remaining dose to be dialed and injected with a second 
pen if the initial dose was incomplete, readjust the dose 
if needed, and remove the needle. Nurses and treatment-
experienced patients also compared the attributes of this 
pen injector with the self-injection devices that they cur-
rently taught or used, based on recall. The entire process 
of instruction, practice, and completing the questionnaire 
took approximately 70 minutes for nurses and 40 minutes 
for patients.
The redesigned prefilled follitropin alfa 900 IU demon-
stration pens were supplied by the manufacturer. All materials 
were new before assessment by each patient/nurse.
Statistical analysis
Data from nurse and patient questionnaires are presented 
using descriptive statistics. Scales rating key performance 
indicators used a 5-point scale where 5 was the best and 1 
was the worst possible outcome. Questions on preferences 
and advantages did not use rating scales and are quoted as a 
percentage of participants who provided each response.
Results
Seventy-three infertile women of reproductive age and 28 
nurses who had worked for 3–30 years in an infertility clinic 
were enrolled in this study; the numbers of patients and nurses 
recruited from each city are shown in Table 1.
Patients had a mean age of 35 (range 24–47) years and 
8% were left-handed (n = 6). The baseline characteristics 
of the patients are summarized in Table 2; 73% (n = 53) of 
patients were treatment-experienced and 27% (n = 20) were 
treatment-naïve.
The nurses all spent at least 80% of their time working 
directly with patients and personally teaching women how 
to use injectable gonadotropins in pens or syringes/vials for 
fertility treatment; 7% were left-handed (n = 2). Injectable 
gonadotropin devices that nurses had taught patients to use 
in the previous 6 months are summarized in Table 3.
All of the patients/nurses participated in the training and 
completed all the sections of the questionnaires that were 
relevant to their experiences, ie, self-injection-naïve patients 
did not answer questions aimed at self-injection-experienced 
patients.
Patients
The specific aspects of the redesigned pen injector that 
patients considered easy to learn are shown in Figure 2. 
Eighty-eight percent (n = 64) of patients found the whole 
process easy to follow and had no trouble learning how to 
use the pen; 70% (n = 51) found it easy to learn how to set 
the dose and how to remove large air bubbles before use.
In the total patient population, 89% (n = 65) of patients 
were either “very” or “quite comfortable” with the zero read-
ing on the dosing scale indicating that the full dose had been 
injected and 88% (n = 64) with pen control when injecting. 
The flexibility to readjust the dose, if the set dose was too 
high/low, was seen as an advantage in learning how to use 
the pen by 85% (n = 62) of patients.
Most (95%, n = 69) patients “strongly/somewhat agreed” 
that they were comfortable with the number of steps involved 
Table 1 Number of nurses and patients recruited from each   
UK city
City Nurses Patients
Birmingham 3 7
Manchester 2 6
Newcastle 3 9
Glasgow 3 5
Southampton 5 14
London 12 32
Total 28 73Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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large air bubble, by 81% (n = 43) for attaching the needle 
onto the pen, by 79% (n = 42) for reading the dosing scale, 
and by 74% (n = 39) for reading the graduated markings on 
the reservoir holder. Eighty-seven percent (n = 46) of the 
injection-experienced patients found it easy to learn how to 
set the dose, 89% (n = 47) to push the dose setting knob when 
injecting, 89% (n = 47) to check that the full dose had been 
injected, 72% (n = 32) to detach and discard the needle, and 
81% (n = 43) to determine any remaining dose required with 
a second pen if the initial dose administered was incomplete. 
Of these injection-experienced patients, 70% (n = 37) claimed 
they would prefer to use the redesigned follitropin alfa pen 
over their current injection device in the future for all their 
injectable fertility medications (Figure 3).
The number of patients with previous experience of the 
Puregon® pen was small (n = 8), reflecting the low number of 
Puregon pen users in the UK and, therefore, is insufficient to 
draw any specific conclusions regarding device preference.
Nurses
All nurses agreed that it was easy to learn how to use the 
redesigned pen and believed it would be easy to teach patients 
how to use it. Based on ease of teaching, 68% (n = 19) of the 
nurses would choose to teach the redesigned pen in prefer-
ence to any other pen or syringe/vial currently available 
(Figure 4).
Regarding aspects of the pen that were easy to teach, 93% 
(n = 26) of nurses thought it was “very” or “somewhat” easy 
to teach patients the overall process of self-administering a 
dose (Figure 5). Compared with other pen injectors, 96% 
(n = 27) of nurses thought it was “much easier” to “as easy” to 
teach patients to use the redesigned follitropin alfa pen; 46% 
(n = 13) thought it was “much” or “somewhat” easier to teach 
patients to use the redesigned follitropin alfa pen, and 50% 
(n = 14) considered it was neither easier nor harder. Almost 
all (96%, n = 27) nurses rated as “very” or “quite” high, the 
range of possible doses that could be administered (due to 
a greater number of dosing increments), and 79% (n = 22) 
were confident that the patient would be able to calculate 
correctly any remaining dose needed with a second pen if an 
incomplete dose was injected with the first pen.
It was “strongly” or “somewhat” agreed by 93% (n = 26) 
of nurses that having the same pen format for a range of inject-
able gonadotropins would make it easier for them to teach 
patients to self-inject and for patients to learn how to self-
inject; 86% (n = 24) of nurses agreed that the redesigned pen 
would significantly reduce their teaching time with patients, 
89% (n = 25) thought it would reduce mistakes when patients 
Table 2 Demographic characteristics of the study patients (n = 73)
Characteristics
Mean (SD) age, years 35 (4.54)
Left-handed, n (%) 6 (8)
Age group, n (%)
  24–30 years 13 (18)
  31–35 years 30 (41)
  36–40 years 21 (29)
  41–47 years 9 (12)
Fertility treatment cycles using self-injected  
gonadotropins undertaken in total, n (%)a
 0 20 (27)
 1 22 (30)
 2 14 (19)
 3 6 (8)
 4 4 (5)
 5 + 7 (10)
Current devices used to inject fertility  
medication, n (%)b
  None 20 (27)
  Follitropin alfa penc 15 (21)
  Follitropin beta pend 8 (11)
  Syringe and vial 31 (42)
Notes: aPercentages do not total 100% due to rounding; bpercentages do not total 
100% due to use/teaching of .1 device; cMerck Serono SA, Geneva, Switzerland; 
dMerck Sharp and Dohme Ltd, Hoddesdon, Hertfordshire, UK. 
Abbreviation: SD, standard deviation.
Table 3 injectable gonadotropin devices that nurses (n = 28) had 
taught patients to use in the previous six months
Device n (%)a
Follitropin alfa penb 24 (86)
Follitropin alfa syringe/vialb 13 (46)
Lutropin alfa syringe/vialb 3 (11)
Chorionic gonadotropin prefilled syringeb 26 (93)
Follitropin beta penc 9 (32)
Follitropin beta syringe/vialc 2 (7)
Chorionic gonadotropin syringe/vialc 14 (50)
Menotropins syringe/viald 25 (89)
Menotropins syringe/viale 6 (21)
Urofollitropin syringe/viale 7 (25)
Chorionic gonadotropin syringe/viald 2 (7)
Notes:  aPercentages do not total 100% due to teaching of .1 device;  bMerck 
Serono  SA,  Geneva,  Switzerland;  cMerck  Sharp  and  Dohme  Ltd,  Hoddesdon, 
Hertfordshire, UK; dFerring international Center SA, Saint-Prex, Switzerland; eiBSA 
institut Biochimique SA, Lugano, Switzerland.
in preparing and giving the injection, and 93% (n = 68) 
believed that using the new pen device would ensure that 
they set the correct dose and administered it in full when 
they self-injected at home.
Among the injection-experienced patients, 66% (n = 35) 
considered that the redesigned follitropin alfa pen was 
easier to learn to use than their current injection method; 
the pen performance was rated as “very high” or “high” by 
83% (n = 44) of patients for ease of learning to remove a Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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The whole process was easy to follow
All patients (n = 73), %
Pushing the dose setting knob while injecting
Setting the dose
Removing any large air bubbles before use
Checking the full dose has been delivered
Reading the dosing scale in the dose window
Fitting the needle onto the pen
Removing and discarding the needle
Calculating/administering a top-up dose* when needed
Reading the gradations on the clear reservoir holder
Figure 2 Aspects of the redesigned follitropin alfa pen that patients found easy to learn.
Note: *Top-up dose; remainder of dose to be dialed and injected in a second pen.
70 19
67 33
38
81 6
25 63
37
11
25
13
12
Total (n = 53)
Treatment-experienced patients, %
GONAL-f  pen (n = 15)
Puregon® pen (n = 8)
Syringe/vial (n = 31)
Prefilled syringe (n = 8)
Prefer redesigned pen
Prefer current pen
Prefer current syringe/vial
®
Figure 3 Summary of device preferences by injection-experienced patients.
self-administered at home, and 96% (n = 27) believed that, 
given a choice, patients would prefer the same pen format for 
administering all their injectable gonadotropin products.
Discussion
This is the first study to report patient and nurse opinions 
on the redesigned follitropin alfa pen for infertility treat-
ment. Patients with infertility, who currently require numer-
ous administration devices to deliver the full spectrum of 
gonadotropins during infertility treatment,3 found the pen 
injector easy to use and most patients found the training on 
use easy to follow. Among the attributes of the redesigned 
pen, patients rated highly the ease of checking that the full 
dose had been injected and the flexibility to readjust the set 
dose. Self-injection-experienced patients generally preferred 
the redesigned pen over their existing injection devices.
There are several reports that infertile patients find pen 
injectors simpler and easier to use than other administration 
methods.1,4–7 In a study of nurse-led training on administration 
of follicle-stimulating hormone, 123 participants attended 
training and completed a questionnaire. Of the patients who 
expressed a preference, 94% preferred a pen device to a 
reconstitution and conventional needle and syringe method. 
The most common reasons given for selection of a prefilled Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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pen were that it was considered to be easy to use, had a simple 
and reliable dosing mechanism, and minimized the chance 
of making a dosing error.1
Prefilled disposable insulin pen injectors have received 
positive ratings for intuitiveness, instruction time, ease of 
use, and acceptance in patient surveys.8,9 Among patients 
with rheumatoid arthritis, a pen injector for a monoclonal 
antibody scored well compared with a prefilled syringe in 
terms of pain and time to inject and was perceived to be easier 
to use and more convenient.10
All the infertility nurses in this study found the pen 
injector easy to learn to use and believed that it would be easy 
to teach patients to use. Most nurses considered that having 
the same device for a range of injectable gonadotropins would 
facilitate teaching patients to self-inject and would reduce 
teaching time. These results are in agreement with those from 
68 25
63 29
70 22
11
27 65
89
4
4 4
4
44
44
4
Total (n = 28)
All nurses, %
GONAL-f  pen (n = 24)
Puregon® pen (n = 9)
Syringe/vial (n = 27)
Prefilled syringe (n = 26)
Prefer redesigned pen
Prefer GONAL-f  pen Prefer current syringe/vial
Prefer Puregon® pen 
®
®
Figure 4 Summary of device preference by infertility nurses teaching patients to self-inject.
93
96
89
89
86
82
75
71 18
21
18
14
4
11
11
3 4
4
4
7
50 50
Overall process of self-administering a dose from start to finish
All nurses (n = 28), %
How to push the dose setting knob when injecting
How to fit needle on pen
How to remove any large air bubbles before use
How to calculate/administer a top-up dose* when needed
How to calculate and set the dose
How to read the gradations on the clear reservoir holder
How to remove and discard the needle
How to read the dosing scale
Very/somewhat difficult (1–2)
Neither easy nor difficult (3)
Very/somewhat easy (4–5)
Figure 5 Fertility nurses’ opinion of ease of teaching for each of the functions of the redesigned follitropin alfa pen.
Note: *Top-up dose; remainder of dose to be dialed and injected in a second pen.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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another study in which pen injectors have been reported to 
be well received by nurses.11
Patients may use several different administration devices 
to deliver the full spectrum of gonadotropins during infertility 
treatment, so there is a need to harmonize the administration 
devices for infertility. A device that could be used to admin-
ister the full range of gonadotropins would have advantages 
for nurses in terms of teaching time and for patients in terms 
of learning time. The use of a common device is also likely 
to reduce administration errors.
A limitation of the present study was that only the rede-
signed follitropin alfa pen was tested and the answers about 
the devices that were used currently were based on recall. 
However, 73% of patients interviewed were self-injection-
experienced and had received fertility treatment with inject-
able gonadotropins in the previous six months. Thus, it is 
considered that results based on patient recall were unlikely 
to have biased the patients’ answers. In addition, the study 
was performed in a viewing facility, was open-label and 
uncontrolled, and assessed perceived ease of learning and 
ease of teaching of the pen device rather than use in an actual 
fertility treatment cycle. Further studies are needed to confirm 
the findings in clinical practice.
Conclusion
In this market research study with infertile patients and 
infertility nurses, the redesigned follitropin alfa pen was 
perceived as easy to learn and easy to teach how to use, and 
was well-accepted. There was also a high level of confidence 
among participants that the full dose of gonadotropin had 
been injected properly and that it was easy to learn how to 
check that the correct dose had been delivered. Moreover, 
most nurses considered that a single platform for delivery 
of the full spectrum of infertility medications that a patient 
might require during treatment would have advantages for 
teaching and learning use for administration.
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Appendix 1
Nurse questionnaire. Duration sections 1 and 2, approximately five minutes; section 3, approximately 15 minutes.
Section 1
Usage and perception of existing devices.
1A. Are you left or right-handed? (Ask all, single code only.)
Left-handed 1 Go to Q1B
Right-handed 2 Go to Q1B
Both 3 Go to Q1B
1B. Which of the following injectable gonadotropin injection devices have you taught your patients to use in the last six 
months? Please tick all which apply. (Ask all, multicode allowed.)
GONAL-f  ® pen (follitropin alfa) 1 Go to Q2A
GONAL-f ® syringe/vial (follitropin alfa) 2 Go to Q2C
Luveris® syringe/vial (lutropin alfa) 3 Go to Q2C
Ovitrelle® prefilled syringe (choriogonadotropin alfa) 4 Go to Q2C
Puregon® pen (follitropin beta) 5 Go to Q2B
Puregon® syringe/vial (follitropin beta) 6 Go to Q2C
Pregnyl® syringe/vial (chorionic gonadotropin) 7 Go to Q2C
Bravelle® syringe/vial (urofollitropin) 8 Go to Q2C
Menopur® syringe/vial (menotropin) 9 Go to Q2C
Merional® syringe/vial (menotropin) 10 Go to Q2C
Fostimon® syringe/vial (urofollitropin) 11 Go to Q2C
Choragon® syringe/vial (chorionic gonadotropin) 12 Go to Q2C
Others (write in) 13 Go to Q2C
2A. The following is a list of attributes relating to the current GONAL-f ® pen. Please rate its performance on the following scale. 
(Randomize order of 2A, 2B, and 2C. Ask Q2A if code 01 (GONAL-f  ® pen) coded at Q1B. Single code per statement.)
1.  Very low
2.  Quite low
3.  Neither low nor high
4.  Quite high
5.  Very high
Range of possible doses which can be prescribed (due to permitted dose increments) 1
ease for the nurse to learn how to use 2
ease for the nurse to teach patients how to use 3
Your confidence that the patient understands how to remove any large air bubbles before use 4
Ease for patient to fit needle onto pen 5
ease for patient to read the dosing scale 6
Your confidence in the patient’s ability to calculate and set the correct dose 7
ease for patient to pull up and prime the injection button 8
ease for patient to push the injection button when injecting 9
ease for patient to administer the injection 10
ease for patient to check that the full dose has been injected 11
Your confidence that the full dose has been injected when patients self-administer at home 12
ease of removing and discarding the needle 13
Your confidence that the patient is able to correctly calculate any top-up dose needed after injection 14
Patient’s satisfaction with the number of steps involved in preparing/giving the injection 15
Your confidence that the patient understands how to use the pen properly 16Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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2B. The following is a list of attributes relating to the current Puregon® pen. Please rate its performance on the following 
scale. (Ask Q2B if code 05 (Puregon® pen) coded at Q1B. Single code per statement.)
1.  Very low
2.  Quite low
3.  Neither low nor high
4.  Quite high
5.  Very high
Range of possible doses which can be prescribed (due to permitted dose increments) 1
ease for the nurse to learn how to use 2
ease for the nurse to teach patients how to use 3
Your confidence that the patient understands how to remove any large air bubbles before use 4
ease for patient to assemble the pen (insert treatment cartridge) 5
Ease for patient to fit needle onto pen 6
ease for patient to read the dosing scale 7
Your confidence in the patient’s ability to calculate and set the correct dose 8
ease for patient to push the injection button when injecting 9
ease for patient to administer the injection 10
ease for patient to check that the full dose has been injected 11
Your confidence that the full dose has been injected when patients self-administer at home 12
ease of removing and discarding the needle 13
Your confidence that the patient is able to correctly calculate any top-up dose needed after injection 14
Patient’s satisfaction with the number of steps involved in preparing/giving the injection 15
Your confidence that the patient understands how to use the pen properly 16
2C. The following is a list of attributes relating to current syringes and vials. Please rate their performance on the follow-
ing scale. (Ask Q2C if codes 02, 03, 04, 06, 07, 08, 09, 10, 11, and 12 (syringes and vials) coded at Q1B. Single code per 
statement.)
1.  Very low
2.  Quite low
3.  Neither low nor high
4.  Quite high
5.  Very high
Range of possible doses which can be prescribed (due to permitted dose increments) 1
ease for the nurse to learn how to use 2
ease for the nurse to teach patients how to use 3
Your confidence that the patient understands how to remove any large air bubbles before use 4
Ease for patient to fit needle onto syringe 5
ease for patient to read the dosing scale 6
ease for patient to mix the treatment in the vial 7
ease for patient to read the gradations on the clear reservoir holder 8
Your confidence in the patient’s ability to calculate and set the correct dose 9
ease for patient to administer the injection 10
ease for patient to check that the full dose has been injected 11
Your confidence that the full dose has been injected when patients self-administer at home 12
ease of removing and discarding the needle 13
Your confidence that the patient is able to correctly calculate any top-up dose needed after injection 14
Patient’s satisfaction with the number of steps involved in preparing/giving the injection 15
Your confidence that the patient understands how to use the syringe properly 16Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Section 2
Reactions to pen demonstration, to be completed after the training session. (Section divider, introduction to be shown to 
respondent.) Now, you will be shown a demonstration on how to use the new pen.* You will have the opportunity to try the 
new pen after the demonstration. Please click NEXT after you had a chance to try the new pen.
3. Below is a list of statements that you may or may not agree with. Please tick all that you agree with having had your 
training session. (Ask all, multicode allowed.)
i found it easy to learn to use the pen 1 Go to Q4
i believe this new pen would be easy for me to teach my patients to use 2 Go to Q4
it will take me less time to teach my patients to use this new pen compared with current pens 3 Go to Q4
it is easy to remove large air bubbles from the new pen 4 Go to Q4
it is easier to read the dosing scale on this new pen compared with other pens/syringes 5 Go to Q4
There are fewer steps involved in preparing the pen for injection compared with current pens 6 Go to Q4
i believe my patients will be able to prepare and inject in a shorter period of time using this pen compared  
with current pens
7 Go to Q4
There is less room for error when setting/adjusting the dose with this new pen compared with current pens 8 Go to Q4
I am confident my patients will be able to regularly administer treatment at the correct dose using this pen 9 Go to Q4
I believe my patients will be more confident in using this new pen than other pens/syringes 10 Go to Q4
4. How comfortable are you with each of the following? (Ask all, single code per statement.) For each attribute please 
indicate whether you are:
5.  Very comfortable
4.  Quite comfortable
3.  Neutral
2.  Quite uncomfortable
1.  Very uncomfortable
The comfort of holding the pen whilst injecting 1 Go to Q5
Pushing the dose setting knob when injecting 2 Go to Q5
The soft click sound when injecting 3 Go to Q5
Pressure required from thumb when injecting 4 Go to Q5
The zero reading on the dosing scale following injection, indicating the full dose has been injected 5 Go to Q5
The control of the pen whilst injecting 6 Go to Q5
5. Please rate the new pen on each of the following attributes. (Ask all, single code per statement.)
5.  Very high
4.  Quite high
3.  Neither low nor high
2.  Quite low
1.  Very low
Range of possible doses which can be prescribed (due to permitted dose increments) 1 Go to Q6
ease for the nurse to learn how to use 2 Go to Q6
ease for the nurse to teach patients how to use 3 Go to Q6
Your confidence that the patient understands how to remove any large air bubbles before use 4 Go to Q6
Ease for patient to fit needle onto pen 5 Go to Q6
ease for patient to read the dosing scale 6 Go to Q6
ease for patients to read the gradations on the clear reservoir holder 7 Go to Q6
Your confidence in the patient’s ability to calculate and set the correct dose 8 Go to Q6
(Continued)
*The term “new pen” refers to the “redesigned follitropin alfa pen.”Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
325
Redesigned follitropin alfa pen injector
(Continued )
ease for patient to push the dose setting knob when injecting 9 Go to Q6
ease for patient to administer the injection 10 Go to Q6
ease for patient to check that the full dose has been injected 11 Go to Q6
Your confidence that the full dose has been injected when patients self-administer at home 12 Go to Q6
ease of removing and discarding the needle 13 Go to Q6
Your confidence that the patient is able to correctly calculate any top-up dose needed after injection 14 Go to Q6
Patient’s satisfaction with the number of steps involved in preparing/giving the injection 15 Go to Q6
Your confidence that the patient understands how to use the pen properly 16 Go to Q6
6. Please rank the importance of the following attributes if recommending any injection device for gonadotropins to a 
fellow fertility nurse like yourself. (Ask all, provide a ranking ladder that respondent can drag and drop each attribute 
onto.)
Range of possible doses which can be prescribed (due to permitted dose increments) 1 Go to Q7
ease for the nurse to learn how to use 2 Go to Q7
ease for the nurse to teach patients how to use 3 Go to Q7
Your confidence that the patient understands how to remove any large air bubbles before use 4 Go to Q7
Ease for patient to fit needle onto pen 5 Go to Q7
ease for patient to read the dosing scale 6 Go to Q7
ease for patients to read the gradations on the clear reservoir holder 7 Go to Q7
Your confidence in the patient’s ability to calculate and set the correct dose 8 Go to Q7
ease for patient to push the dose setting knob when injecting 9 Go to Q7
ease for patient to administer the injection 10 Go to Q7
ease for patient to check that the full dose has been injected 11 Go to Q7
Your confidence that the full dose has been injected when patients self-administer at home 12 Go to Q7
ease of removing and discarding the needle 13 Go to Q7
Your confidence that the patient is able to correctly calculate any top-up dose needed after injection 14 Go to Q7
Patient’s satisfaction with the number of steps involved in preparing/giving the injection 15 Go to Q7
Your confidence that the patient understands how to use the device properly 16 Go to Q7
7. (Ask all, single code per statement.) Overall, how easy do you think it will be to teach patients how to use the new pen 
compared with:
5.  Much easier to teach
4.  Somewhat easier to teach
3.  No better nor worse
2.  Somewhat harder to teach
1.  Much harder to teach
The current GONAL-f ® pen? 1 Go to Q8 Only show this option if code
The current Puregon® pen? 2 Go to Q8
Current syringes and vials? 3 Go to Q8
8. How confident are you in teaching patients how to use the new pen after your training? (Ask all, single code only.)
5.  Very confident
4.  Quite confident
3.  Neutral
2.  Not very confident
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9. Which of the following aspects of the new pen, if any, do you see as advantages over current injection methods. Please 
tick all that apply. (Ask all, multicode.)
Transparent (clear) reservoir holder 1 Go to Q10
Gradations on the reservoir holder 2 Go to Q10
Needle attachment and removal 3 Go to Q10
Flexibility to readjust dose (if set dose is too high/low) 4 Go to Q10
Single press release for injection 5 Go to Q10
The soft click sound when injecting 6 Go to Q10
Pressure required from thumb when injecting 7 Go to Q10
visibility of dosing window 8 Go to Q10
Ability to see any top-up dose needed after injection 9 Go to Q10
The zero reading on the dosing scale following injection, indicating the full dose has been injected 10 Go to Q10
Additional confidence that the full dose has been injected compared with current pens/syringes 11 Go to Q10
Section 3
Evaluation of the pen and how easy it was to train patients to use it – to be completed after the nurses train the patients to use 
the pen. (Section divider, introduction to be shown to respondent.) Now, you will have the opportunity to demonstrate and train 
some patients on how to use the new pen. Please click NEXT after you have trained the patients on how to use the new pen.
10. On a scale of 1–5, how easy has it been to teach patients to perform each of the following functions of the new pen? 
(Ask all, single code per statement.)
5.  Very easy
4.  Somewhat easy
3.  Neither easy nor difficult
2.  Somewhat difficult
1.  Very difficult
How to to remove any large air bubbles before use 1 Go to Q11
How to fit needle on pen 2 Go to Q11
How to read the gradations on the clear reservoir holder 3 Go to Q11
How to read the dosing scale 4 Go to Q11
How to calculate and set the dose 5 Go to Q11
How to push the dose setting knob when injecting 6 Go to Q11
How to calculate/administer a top-up dose when needed 7 Go to Q11
How to remove and discard the needle 8 Go to Q11
Overall process of self-administering a dose from start to finish 9 Go to Q11
Others (please state) 10 Go to Q11
11. Based on your experience with the new pen today, to what extent would you be likely to recommend it to a fellow fertility 
nurse like yourself? (Ask all, single code only.)
5.  Very likely
4.  Likely
3.  Neither likely nor unlikely
2.  Unlikely
1.  Very unlikely
12. Now that you have trained some patients to use the new pen, to what extent do you agree with the following statements? 
(Ask Q12 if code 01 and/or code 05 (pens) coded at Q1B.)
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3.  Neither agree nor disagree
2.  Somewhat disagree
1.  Strongly disagree
it will take me less time to teach my patients to use this new pen compared with current pens 1 Go to Q13
There are fewer steps involved in preparing and giving the injection with the new pen compared with current pens 2 Go to Q13
There is less room for error when setting/adjusting the correct dose with this new pen compared with current pens 3 Go to Q13
i believe my patients will be able to regularly administer the correct dose with this new pen 4 Go to Q13
i believe my patients will be able to prepare and give the injection using this new pen in a shorter period of time  
compared with current pens
5 Go to Q13
I believe my patients will be able to confidently calculate/administer any top-up dose needed with this pen 6 Go to Q13
I believe my patients will be confident in using this new pen with minimal queries once they are trained by me 7 Go to Q13
13. Overall, how easy do you believe is it to teach patients to use the new pen compared with current pens? (Ask all, single 
code.)
5.  Much easier to teach
4.  Somewhat easier to teach
3.  Neither harder nor easier than current devices
2.  Somewhat harder to teach
1.  Much harder to teach
14. Based on ease of teaching, if you only had one choice, which of the following would you prefer to teach patients how 
to use for their injectable follicle-stimulating hormone medication? (Ask all, single code.)
Current GONAL-f ® pen 1 Go to Q15
Current Puregon® pen 2 Go to Q15
Current syringes and vials 3 Go to Q15
This new pen 4 Go to Q15
15. This new pen will be produced for Merck Serono injectable gonadotropins. In the future, additional gonadotropins will 
be available in separate pens, just like this. To what extent do you agree with each of the following statements? (Ask all, 
single code per statement.)
5.  Strongly agree
4.  Somewhat agree
3.  Neither agree nor disagree
2.  Somewhat disagree
1.  Strongly disagree
i am more likely to recommend injectable gonadotropins from Merck Serono if they each come in pens like this one 1 Finish
Having the same pen format for a range of injectable gonadotropins will make it easier for me to teach my patients to self-inject 2 Finish
Having the same pen format for a range of injectable gonadotropins will significantly reduce my teaching time with patients 3 Finish
Having the same pen format for a range of injectable gonadotropins will make it easier for patients to learn to self-inject 4 Finish
Given a choice, patients would ideally prefer to use the same pen format for all of their injectable gonadotropins 5 Finish
Having the same pen format for a number for the different injectable gonadotropins would reduce mistakes when patients  
self-administer at home
6 Finish
This will increase my likelihood to recommend Merck Serono products to the physician 7 Finish
Finally, can we contact you again to discuss any points that may be raised following your participation in this research 
project?
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Appendix 2
Patient questionnaire. Approximate duration 15 minutes.
Section 1
Evaluation of previously used devices.
1A. Are you left or right-handed? (Ask all, single code only.)
Left-handed 1 Go to Q1B
Right-handed 2 Go to Q1B
Both 3 Go to Q1B
1B. Do you currently use, or have you ever used in the past, a self-administered injectable medication for fertility treatment? 
(Ask all, single code only.)
Yes 1 Go to Q1C (Code as “injection experienced”)
No 2 Go to Q2 (Code as “injection naive”)
1C. Which of the following fertility treatments have you used in the past six months? Please tick all which apply. (Ask all, 
multicode allowed.)
GONAL-f  ® pen (follitropin alfa) 1 Go to Q1D
GONAL-f  ® syringe/vial (follitropin alfa) 2 Go to Q1D
Luveris® syringe/vial (lutropin alfa) 3 Go to Q1D
Ovitrelle® prefilled syringe (choriogonadotropin 
alfa)
4 Go to Q1D
Puregon® pen (follitropin beta) 5 Go to Q1D
Puregon® syringe/vial (follitropin beta) 6 Go to Q1D
Pregnyl® syringe/vial (chorionic gonadotropin) 7 Go to Q1D
Bravelle® syringe/vial (urofollitropin) 8 Go to Q1D
Menopur® syringe/vial (menotropin) 9 Go to Q1D
Merional® syringe/vial (menotropin) 10 Go to Q1D
Fostimon® syringe/vial (urofollitropin) 11 Go to Q1D
Choragon® syringe/vial (chorionic 
gonadotropin)
12 Go to Q1D
Others (write in) 13 Go to Q1D
1D. Which of the following injection methods do you currently use to inject your fertility medication? Please tick all which 
apply. (Ask all, multicode allowed.)
GONAL-f  ® pen 1 Go to Q2
Puregon® pen 2 Go to Q2
Syringe and vial 3 Go to Q2
Prefilled syringe 4 Go to Q2
Section 2
Evaluation of new pen* and how easy it is to learn to use. (To be completed after the patient has received the demonstra-
tion/training from the nurse and has had a chance to try the pen themselves.) All injection-experienced and injection-naive 
patients to answer all questions in this section. (Section divider, introduction to be shown to respondent.) Now, you will be 
shown a demonstration on how to use the new pen by a qualified fertility nurse. You will have the opportunity to try the new 
pen after the demonstration. Please click NEXT after you had a chance to try the new pen after the demonstration.
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2. Which of the following aspects of the new pen did you find easy to learn? Please select all which apply. (Ask all, 
multicode.)
The whole process was easy to follow and i had no trouble learning how to use the new pen 1 Go to Q3
Learning how to fit the needle onto the pen 2 Go to Q3
Learning how to remove any large air bubbles before use 3 Go to Q3
Learning how to set the dose 4 Go to Q3
Learning how to read the dosing scale in the dose window on the side of the pen 5 Go to Q3
Learning how to read the gradations on the clear reservoir holder 6 Go to Q3
Learning how to push the dose setting knob when injecting 7 Go to Q3
Learning how to check the full dose has been delivered 8 Go to Q3
Learning how to calculate/administer a top-up dose when needed 9 Go to Q3
Learning how to remove and discard the needle 10 Go to Q3
Others (write in) 11 Go to Q3
3. How comfortable are you with the following? (Ask all, single code per statement.) For each attribute please indicate 
whether you are:
5.  Very comfortable
4.  Quite comfortable
3.  Neither comfortable nor uncomfortable
2.  Quite uncomfortable
1.  Very uncomfortable
The comfort of holding the pen whilst injecting 1 Go to Q4
Pushing the dose setting knob when injecting 2 Go to Q4
The soft click sound when injecting 3 Go to Q4
Pressure required from thumb when injecting 4 Go to Q4
The zero reading on the dosing scale following injection, indicating the full dose has been injected 5 Go to Q4
The control of the pen whilst injecting 6 Go to Q4
4. Which of the following aspects, if any, do you see as advantages when learning how to use the new pen? Please tick all that 
apply. (Ask all, multicode.)
Transparent (clear) reservoir holder 1 Go to Q5
Gradations on the clear reservoir holder 2 Go to Q5
Needle attachment and removal 3 Go to Q5
Flexibility to readjust dose (if set dose is too high/low) 4 Go to Q5
Single press release for injection 5 Go to Q5
Soft click sound when injecting 6 Go to Q5
Pressure required from thumb when injecting 7 Go to Q5
visibility of dosing window 8 Go to Q5
Ability to view any top-up dose needed after injection 9 Go to Q5
The zero reading on the dosing scale following injection, indicating the full dose has been injected 10 Go to Q5
Additional confidence that the full dose has been injected, compared with your current method of 
injection
11 Go to Q5
Section 3
Comparison of new pen with currently used pen/syringe. Only ask for those coded 01 at Q1B. Only injection-experienced 
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5. The following is a list of attributes relating to the new pen and the injection pen, syringe/vial or prefilled syringe which you 
currently use. (Allow comparison between new pen and each device coded at Q1D, show all devices on screen to allow direct 
comparison.) Need to add option of prefilled syringe to link. Please rate their performance on a scale of 1–5 where:
1.  Very low
2.  Quite low
3.  Neither low nor high
4.  High
5.  Very high
easy to learn how to use 1 Go to Q6
easy to learn how to remove any large air bubbles before use 2 Go to Q6
Easy to learn how to fit the needle onto the pen 3 Go to Q6
easy to learn how to read the dosing scale 4 Go to Q6
easy to learn how to read the gradations on the clear reservoir holder 5 Go to Q6 (Ask for new pen only)
easy to learn how to calculate and set the dose 6 Go to Q6
Flexibility to readjust dose (if set dose is too high/low) 7 Go to Q6
easy to learn how to push the dose setting knob when injecting 8 Go to Q6
easy to learn how to administer the injection 9 Go to Q6
easy to check that the full dose has been injected 10 Go to Q6
easy to remove and discard the needle 11 Go to Q6
easy to calculate any top-up dose needed after injection 12 Go to Q6
Number of steps involved in preparing/giving the injection 13 Go to Q6
6. Now that you are trained and have tried using the new pen, to what extent do you agree with the following statements? 
(Single code per statement.)
5.  Strongly agree
4.  Somewhat agree
3.  Neither agree nor disagree
2.  Somewhat disagree
1.  Strongly disagree
it was easier to learn how to use this new pen compared with my current injection method 1 Go to Q7
it is easier to remove large air bubbles from the new pen compared with my current injection method 2 Go to Q7
it is easier to read the dosing scale on this new pen compared with my current injection method 3 Go to Q7
it takes less time for me to prepare the new pen for my injection compared to my current injection method 4 Go to Q7
There are fewer steps involved in preparing/giving the injection with the new pen compared with my  
current injection method
5 Go to Q7
There is less room for error in setting/adjusting the correct dose with this new pen compared  
with my current injection method
6 Go to Q7
I am more confident I will be able to administer the correct dose using this new pen compared  
with my current injection method
7 Go to Q7
I am more confident I will be able to calculate any top-up dose needed with this new pen, compared  
with my current injection method
8 Go to Q7
I would be more confident in using this new pen than my current injection method 9 Go to Q7
I am confident I can self-administer using this new pen without any further help from my nurse in the future 10 Go to Q7
There is less wastage of medication compared with my current injection method as i will use all the medication  
in the pen before starting a new pen
11 Go to Q7Patient Preference and Adherence
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7. Based on your experience today, which of the following statements best reflects your opinion of this new pen as a delivery 
system for an injectable fertility treatment? (Single code only.)
I believe this pen is definitely better than the pens and/or syringes of which I have experience 1 Go to Q8
i believe this is somewhat better than the pens and/or syringes of which i have experience 2 Go to Q8
i believe this is neither better nor worse than pens and/or syringes of which i have experience 3 Go to Q8
i think this pen is not quite as good as the pen and/or syringes of which i have experience 4 Go to Q8
This pen is inferior to the pen and/or syringes of which i have experience 5 Go to Q8
Section 4
Agreement with statements and preference for new pen. (All patients [injection-experienced and injection-naive] to answer 
all questions in this section.)
8. Now that you are trained and have tried using the new pen, to what extent do you agree with the following statements? 
(Single code per statement.)
5.  Strongly agree
4.  Somewhat agree
3.  Neither agree nor disagree
2.  Somewhat disagree
1.  Strongly disagree
i believe that this new pen will ensure i inject the full dose properly when i self-administer at home 1 Go to Q9
i believe this new pen will ensure i calculate and set the correct dose when i self-administer at home 2 Go to Q9
i am comfortable with the number of steps involved in preparing and giving the injection 3 Go to Q9
9. Assuming your nurse or doctor gave you a choice, which of the following would you prefer to use in the future for all 
your injectable fertility medications? (Injection-experienced patients only to answer, single code only.)
My current method of injection – pen 1 Finish
My current method of injection – syringe and vial 2 Finish
This new pen 3 Finish
Finally, can we contact you again to discuss any points that may be raised following your participation in this research 
project?
Answer: Yes No